The consolidated operating profit of Hanmi Science, the holding company of Hanmi Pharmaceutical Group, for the second quarter of this year increased by 30.7% compared to the same period last year, reaching 34.6 billion won.
Hanmi Science, the holding company of Hanmi Group, and its core business entity Hanmi Pharmaceutical announced their provisional results for the second quarter on the 25th.
Hanmi Science transitioned to a professional management system with CEO Kim Jae-kyu taking office in March of this year, and achieved significant improvement in its second quarter results.
In the second quarter, Hanmi Science reported sales of 338.3 billion won, a 9.4% increase compared to the same period last year, and a net profit of 28.3 billion won, up 39.2%. Cumulative sales for the first half of the year reached 670.4 billion won, an increase of 6.5% from the previous year, with an operating profit of 61.7 billion won and a net profit of 52.8 billion won.
The operating profit of Hanmi Pharmaceutical for the second quarter was 60.4 billion won, a 4% increase compared to the same period last year. Sales during the same period decreased by 4.5% to 361.3 billion won, and net profit fell by 8.6% to 43 billion won.
Hanmi Pharmaceutical noted, "We invested 50.4 billion won in research and development, which is about 14% of this year's first half sales," adding, "We plan to present clinical results of major new drug pipelines at various academic conferences in the second half of the year."
Hanmi Pharmaceutical's prescription performance outside of hospitals for the first half surpassed 500 billion won.
The second quarter prescription sales of the combination drug 'Rosuzet' for treating dyslipidemia increased by 9.5% year-on-year to 56 billion won. The hypertension product line 'Amojealtan Family' generated sales of 36 billion won, while the gastroesophageal reflux disease product line 'Esomezol Family' contributed 15.7 billion won in sales.
The company expressed optimism, stating, "Based on the prescription performance outside of hospitals, we expect to smoothly achieve the remarkable record of being the top in the pharmaceutical industry's outpatient prescriptions for eight consecutive years."
However, the second quarter performance of Beijing Hanmi Pharmaceutical, the company's local subsidiary in China, decreased compared to the previous year. Beijing Hanmi's second quarter sales fell by about 12% to 86.7 billion won, its operating profit dropped by about 33.7% to 16.7 billion won, and net profit decreased by approximately 33.2% to 15.5 billion won year-on-year.
The company noted, "We are pushing for management efficiency at Beijing Hanmi, and as the inventory depletion in the market continues, performance is recovering."
Hanmi Science announced that it will accelerate the technology export of existing pipelines in obesity metabolism, oncology, and rare diseases to enhance the value of Hanmi Pharmaceutical's new drugs, while also actively expanding internal and external open innovation and discovering promising new modalities to support growth.
At the same time, we plan to actively discover and cultivate future promising businesses with high market potential, such as digital healthcare and senior and kids care, to sustain our growth.
Kim Jae-kyu, CEO of Hanmi Science, stated, "As a holding company, we will faithfully fulfill our role in providing future business direction for each subsidiary and affiliate, and lead the holding company to have diverse self-generated revenues through direct business." He also added, "We will strive to maximize shareholder value through differentiated competitiveness by predicting and executing the overall group's future growth strategy."